LINZOAX

Description

LINZOAX is a paediatric Linezolid oral suspension specially formulated to combat serious bacterial infections caused by susceptible and resistant Gram-positive organisms. It works by inhibiting bacterial protein synthesis, thereby stopping the growth and multiplication of infection-causing bacteria. It is particularly effective against resistant pathogens, making it a reliable option in difficult-to-treat infections.

LINZOAX is indicated for the treatment of pneumonia, skin and soft tissue infections, and other serious bacterial infections in children. Its pleasant oral suspension formulation ensures convenient administration and improved compliance in paediatric patients while providing effective antibacterial coverage with trusted safety and efficacy.

Indications:

• Treats bacterial infections in children
• Effective in infections of the lungs (pneumonia)
• Manages skin and soft tissue infections
• Effective against Methicillin-Resistant Staphylococcus Aureus (MRSA) infections
• Used in Vancomycin-Resistant Enterococcus (VRE) infections

Therapeutic Segment Positioning:

Antibiotics